BACKGROUND:Baloxavir marboxil (BXM), the oral prodrug of baloxavir acid (BXA), greatly reduces virus titers as well as influenza symptoms of uncomplicated influenza in patients.OBJECTIVES:To investigate the pharmacokinetic profiles of BXA and its efficacy against influenza A virus infection in ferrets.METHODS:Ferrets were dosed orally with BXM (10 and 30?mg/kg twice daily for 1?day), oseltamivir phosphate (OSP) (5?mg/kg twice daily for 2?days) or vehicle to measure the antiviral effects of BXM and OSP. The pharmacokinetic parameters of BXA was determined after single oral dosing of BXM.RESULTS:The maximum plasma concentrations of BXA were observed at 1.50 and 2.00?hours with the two BXM doses, which then declined with an elimination half-life of 6.91 and 4.44?hours, respectively. BXM at both doses remained detectable in the plasma in ferrets, which may be due to higher stability in liver microsomes. BXM (10 and 30?mg/kg twice daily) treatment at Day 1 post-infection (p.i.) reduced virus titers by ≥3 log10 of the 50% tissue culture infective doses by Day 2, which was significantly different compared with vehicle or OSP. Body temperature drops over time were significantly greater with BXM than with vehicle or OSP. Significant reduction in virus titers was also demonstrated when BXM was administrated after symptom onset at Day 2 p.i. compared with vehicle and OSP, although body temperature changes largely overlapped between Day 2 and Day 4.CONCLUSIONS:The results highlight the rapid antiviral action of BXM with post-exposure prophylaxis or therapeutic dosing in ferrets and offer support for further research on prevention of influenza virus infection and transmission.? 2020 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
展开▼
